Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Delusions of Parasitosis Treatment & Management

  • Author: Noah S Scheinfeld, JD, MD, FAAD; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Jan 20, 2016
 

Medical Care

In 2014, an article on delusions of parasitosis stressed the need of the physician to establish a therapeutic alliance with patients suffering from the condition. Without this alliance it is difficult to convince patients to take the necessary medications. The first meeting with a patient with DP can set the tone for all subsequent encounters.[37]

Another article states that the patient's autonomy must be respected in all encounters.

The physician must provide provide full information regarding the treatment plan and seek consent before starting treatment or asking the patient to seek a psychiatric referral.[38]

There has been an increase in combined psychiatric/dermatologic approaches to treating delusions of parasitosis, using a multidisciplinary approach with dermatologists working with psychiatrists and others. One clinic in Singapore used this approach and noted that delusions of parasitosis was the most common psychophysiologic disorder. The study noted that 20% of patients had psychiatric disorders underlying their skin problems and that trichotillomania and dermatitis artefacta were also observed.[11]

The only clear method to clear the delusion that underlies delusions of parasitosis is the administration of psychotropic medications. However, the condition can remit on its own. If the sensation of itch is related to some actual disease or substance use rather than a monosymptomatic hypochondriacal psychosis, the disease can be treated, or the substance inducing the sensation can be eliminated.

It is vitally important that the practitioner does not "use the delusion" to encourage the patient to accept certain treatments. While getting the patient to take a medication, such as risperidone, may help the condition, telling them that it is a medication that "kills the parasites" reinforces and validates the delusion. Even giving the patient a course of topical permethrin "just in case" may strengthen the delusion and make it that much more difficult later on. Every delusions of parasitosis patient can recount the visit on which his or her suspicions of infestation were "confirmed."

Serotonergic antidepressants may have a role in the treatment of these patients.[39, 40]

Reichenberg et al[41] reported on a patient whose delusions of parasitosis was cured overnight by having him stop taking cetirizine and doxepin (25 mg), as well as any over-the-counter medications.

Rocha and Hara[42] reported that aripiprazole at 15 mg for 8 weeks and then 7.5 mg/d was effective for delusions of parasitosis treatment. They stated:

Aripiprazole has a unique pharmacologic profile that is different from other atypical antipsychotic drugs. It is considered a partial dopaminergic agonist acting on both postsynaptic dopamine D2 receptors and presynaptic autoreceptors. It acts as a weak stimulator (so-called “partial” agonist) at dopamine D2 receptors, with the potential for exerting either antagonistic (inhibitory) or agonistic (stimulating) effects, depending on the sensitivity of the receptors and availability of dopamine, its natural agonist in the brain. In addition, aripiprazole displays partial agonism at serotonin (1A) receptors and antagonism at serotonin (2A) receptors.

Secondary delusional parasitosis was treated successfully with the combination of citalopram and clozapine. What relevance this has for treating primary delusions of parasitosis is unclear. A middle-aged woman treated with extended-release mixed amphetamine salts developed secondary delusions of parasitosis, which resolved with stopping the medication, underlying the need to assess medication usage before making a diagnosis of delusions of parasitosis.

Ladizinski et al also report that aripiprazole may be a useful treatment for delusions of parasitosis.[43]

Szepietowski et al[44] sent out 172 specially designed questionnaires to dermatologists regarding delusions of parasitosis patients; 118 responded. The questions and resulting percentages are as follows:

  • Had seen at least one patient with delusions of parasitosis - 84.7%
  • Had 1-2 cases of delusions of parasitosis over the preceding 5 years - 33%
  • Had seen 3-5 such patients over the preceding 5 years - 28%
  • Had diagnosed no cases of delusions of parasitosis during the past 5 years - 23%
  • Had more than 10 patients with delusions of parasitosis over the past 5 years - 7%
  • Were currently treating a patient with delusions of parasitosis - 20%
  • Always request a psychiatric opinion about their patients with delusions of parasitosis - 40.75%
  • Often ask for a psychiatric opinion about their patients with delusions of parasitosis - 28.8%
  • Use their own pharmacological treatment, mostly sedatives and anxiety-relieving drugs - 15.3%.
Next

Consultations

A psychiatrist should be consulted if the dermatologist cannot or will not prescribe the necessary medications. Most patients with delusions of parasitosis are reluctant to see a psychiatrist, and the dermatologist may be more successful in giving the referral if they have gained the patient's trust after several clinic visits instead of immediately after meeting the patient.

Previous
 
 
Contributor Information and Disclosures
Author

Noah S Scheinfeld, JD, MD, FAAD Assistant Clinical Professor, Department of Dermatology, Weil Cornell Medical College; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Assistant Attending Dermatologist, New York Presbyterian Hospital; Assistant Attending Dermatologist, Lenox Hill Hospital, North Shore-LIJ Health System; Private Practice

Noah S Scheinfeld, JD, MD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Abbvie<br/>Received income in an amount equal to or greater than $250 from: Optigenex<br/>Received salary from Optigenex for employment.

Specialty Editor Board

David F Butler, MD Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: American Medical Association, Alpha Omega Alpha, Association of Military Dermatologists, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey Meffert, MD Associate Clinical Professor of Dermatology, University of Texas School of Medicine at San Antonio

Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Franklin Flowers, MD Department of Dermatology, Professor Emeritus Affiliate Associate Professor of Pathology, University of Florida College of Medicine

Franklin Flowers, MD is a member of the following medical societies: American College of Mohs Surgery

Disclosure: Nothing to disclose.

References
  1. Savely VR, Leitao MM, Stricker RB. The mystery of Morgellons disease: infection or delusion?. Am J Clin Dermatol. 2006. 7(1):1-5. [Medline].

  2. Koblenzer CS. The challenge of Morgellons disease. J Am Acad Dermatol. 2006 Nov. 55(5):920-2. [Medline].

  3. Waddell AG, Burke WA. Morgellons disease?. J Am Acad Dermatol. 2006 Nov. 55(5):914-5. [Medline].

  4. Murase JE, Wu JJ, Koo J. Morgellons disease: a rapport-enhancing term for delusions of parasitosis. J Am Acad Dermatol. 2006 Nov. 55(5):913-4. [Medline].

  5. Marris E. Mysterious 'Morgellons disease' prompts US investigation. Nat Med. 2006 Sep. 12(9):982. [Medline].

  6. Harvey WT. Morgellons disease. J Am Acad Dermatol. 2007 Apr. 56(4):705-6. [Medline].

  7. Walling HW, Swick BL. Psychocutaneous syndromes: a call for revised nomenclature. Clin Exp Dermatol. 2007 May. 32(3):317-9. [Medline].

  8. Hylwa SA, Foster AA, Bury JE, Davis MD, Pittelkow MR, Bostwick JM. Delusional infestation is typically comorbid with other psychiatric diagnoses: review of 54 patients receiving psychiatric evaluation at Mayo Clinic. Psychosomatics. 2012 May. 53(3):258-65. [Medline].

  9. Fellner MJ. New findings in delusions of parasitosis. Skinmed. 2012 Mar-Apr. 10(2):72-4. [Medline].

  10. Reichenberg JS, Magid M, Jesser CA, Hall CS. Patients labeled with delusions of parasitosis compose a heterogenous group: a retrospective study from a referral center. J Am Acad Dermatol. 2013 Jan. 68(1):41-6, 46.e1-2. [Medline].

  11. Freudenmann RW, Lepping P, Huber M, et al. Delusional infestation and the specimen sign: a European multicentre study in 148 consecutive cases. Br J Dermatol. 2012 Aug. 167(2):247-51. [Medline].

  12. Levin EC, Gieler U. Delusions of parasitosis. Semin Cutan Med Surg. 2013 Jun. 32(2):73-7. [Medline].

  13. Heller MM, Wong JW, Lee ES, Ladizinski B, Grau M, Howard JL, et al. Delusional infestations: clinical presentation, diagnosis and treatment. Int J Dermatol. 2013 Jul. 52(7):775-83. [Medline].

  14. Patel V, Koo JY. Delusions of parasitosis; suggested dialogue between dermatologist and patient. J Dermatolog Treat. 2015 Oct. 26(5):456-60. [Medline].

  15. Monk BE, Rao YJ. Delusions of parasitosis with fatal outcome. Clin Exp Dermatol. 1994 Jul. 19(4):341-2. [Medline].

  16. Aw DC, Thong JY, Chan HL. Delusional parasitosis: case series of 8 patients and review of the literature. Ann Acad Med Singapore. 2004 Jan. 33(1):89-94. [Medline].

  17. Bouree P, Benattar B, Perivier S. [Ekbom syndrome or delusional parasitosis]. Rev Prat. 2007 Mar 31. 57(6):585-9. [Medline].

  18. Goddard J. Seasonality of delusions of parasitosis. J Agromedicine. 2003. 9(1):23-6. [Medline].

  19. Vila-Rodriguez F, Macewan BG. Delusional parasitosis facilitated by web-based dissemination. Am J Psychiatry. 2008 Dec. 165(12):1612. [Medline].

  20. Edison KE, Slaughter JR, Hall RD. Psychogenic parasitosis: a therapeutic challenge. Mo Med. 2007 Mar-Apr. 104(2):132-7; quiz 137-8. [Medline].

  21. Le L, Gonski PN. Delusional parasitosis mimicking cutaneous infestation in elderly patients. Med J Aust. 2003 Aug 18. 179(4):209-10. [Medline].

  22. Bury JE, Bostwick JM. Iatrogenic delusional parasitosis: a case of physician-patient folie a deux. Gen Hosp Psychiatry. 2010 Mar-Apr. 32(2):210-2. [Medline].

  23. Thakkar A, Ooi KG, Assaad N, Coroneo M. Delusional infestation: are you being bugged?. Clin Ophthalmol. 2015 Jun. 2;9:967-70. [Medline].

  24. Gassiep I, Griffin PM. Delusions of disseminated fungosis. Case Rep Infect Dis. 2014. 2014:458028. [Medline].

  25. Koo J, Lee CS. Delusions of parasitosis. A dermatologist's guide to diagnosis and treatment. Am J Clin Dermatol. 2001. 2(5):285-90. [Medline].

  26. Swick BL, Walling HW. Drug-induced delusions of parasitosis during treatment of Parkinson's disease. J Am Acad Dermatol. 2005 Dec. 53(6):1086-7. [Medline].

  27. Lopez PR, Rachael T, Leicht S, Smalligan RD. Gabapentin-induced delusions of parasitosis. South Med J. 2010. 103:711-2. [Medline].

  28. Steinert T, Studemund H. Acute delusional parasitosis under treatment with ciprofloxacin. Pharmacopsychiatry. 2006 Jul. 39(4):159-60. [Medline].

  29. Tran TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malar J. 2006 Aug 23. 5:74. [Medline].

  30. Krauseneck T, Soyka M. Delusional parasitosis associated with pemoline. Psychopathology. 2005 Mar-Apr. 38(2):103-4. [Medline].

  31. Guarneri F, Guarneri C, Mento G, Ioli A. Pseudo-delusory syndrome caused by Limothrips cerealium. Int J Dermatol. 2006 Mar. 45(3):197-9. [Medline].

  32. Ghaffari-Nejad A, Toofani K. Delusion of oral parasitosis in a patient with major depressive disorder. Arch Iran Med. 2006 Jan. 9(1):76-7. [Medline].

  33. Duggal H, Singh I. Delusional parasitosis as a presenting feature of dementia. J Neuropsychiatry Clin Neurosci. 2010 Winter. 22(1):123.E11-12. [Medline].

  34. Trager MJ, Hwang TN, McCulley TJ. Delusions of parasitosis of the eyelids. Ophthal Plast Reconstr Surg. 2008 Jul-Aug. 24(4):317-9. [Medline].

  35. Huber M, Karner M, Kirchler E, Lepping P, Freudenmann RW. Striatal lesions in delusional parasitosis revealed by magnetic resonance imaging. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12. 32(8):1967-71. [Medline].

  36. Hylwa SA, Bury JE, Davis MD, Pittelkow M, Bostwick JM. Delusional Infestation, Including Delusions of Parasitosis: Results of Histologic Examination of Skin Biopsy and Patient-Provided Skin Specimens. Arch Dermatol. May 2011. [Medline].

  37. Patel V, Koo JY. Delusions of Parasitosis; Suggested Dialogue between Dermatologist and Patient. J Dermatolog Treat. 2014 Dec 9. 1-15. [Medline].

  38. Söderfeldt Y, Groß D. Information, consent and treatment of patients with morgellons disease: an ethical perspective. Am J Clin Dermatol. 2014 Apr. 15(2):71-6. [Medline].

  39. Scheinfeld N. Delusions of parasitiosis: a case with a review of its course and treatment. Skinmed. 2003 Nov-Dec. 2(6):376-8. [Medline].

  40. Wenning MT, Davy LE, Catalano G, Catalano MC. Atypical antipsychotics in the treatment of delusional parasitosis. Ann Clin Psychiatry. 2003 Sep-Dec. 15(3-4):233-9. [Medline].

  41. Reichenberg JS, Magid M, Drage LA. A cure for delusions of parasitosis. J Eur Acad Dermatol Venereol. 2007 Nov. 21(10):1423-4. [Medline].

  42. Rocha FL, Hara C. Aripiprazole in delusional parasitosis: Case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13. 31(3):784-6. [Medline].

  43. Ladizinski B, Busse KL, Bhutani T, Koo JY. Aripiprazole as a viable alternative for treating delusions of parasitosis. J Drugs Dermatol. Dec 2010. 9:1531-2. [Medline].

  44. Szepietowski JC, Salomon J, Hrehorow E, Pacan P, Zalewska A, Sysa-Jedrzejowska A. Delusional parasitosis in dermatological practice. J Eur Acad Dermatol Venereol. 2007 Apr. 21(4):462-5. [Medline].

  45. Elmer KB, George RM, Peterson K. Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol. 2000 Oct. 43(4):683-6. [Medline].

  46. Friedmann AC, Ekeowa-Anderson A, Taylor R, Bewley A. Delusional parasitosis presenting as folie à trois: successful treatment with risperidone. Br J Dermatol. 2006 Oct. 155(4):841-2. [Medline].

  47. Meehan WJ, Badreshia S, Mackley CL. Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol. 2006 Mar. 142(3):352-5. [Medline].

  48. Freudenmann RW, Schönfeldt-Lecuona C. Delusional parasitosis: treatment with atypical antipsychotics. Ann Acad Med Singapore. 2005 Jan. 34(1):141-2; author reply 142. [Medline].

  49. Atilganoglu U, Ugurad I, Arikan M, Ergun SS. Monosymptomatic hypochondriacal psychosis presenting with recurrent oral mucosal ulcers and multiple skin lesions responding to olanzapine treatment. Int J Dermatol. 2006 Oct. 45(10):1189-92. [Medline].

  50. van Vloten WA. Pimozide: use in dermatology. Dermatol Online J. 2003 Mar. 9(2):3. [Medline].

  51. Fellner MJ, Majeed MH. Tales of bugs, delusions of parasitosis, and what to do. Clin Dermatol. 2009 Jan-Feb. 27(1):135-8. [Medline].

  52. Bennassar A, Guilabert A, Alsina M, Pintor L, Mascaro JM Jr. Treatment of delusional parasitosis with aripiprazole. Arch Dermatol. 2009 Apr. 145(4):500-1. [Medline].

  53. Lim GC, Chen YF, Liu L, Huang SC, Lin KK, Hsiao CH. Camphor-related self-inflicted keratoconjunctivitis complicating delusions of parasitosis. Cornea. 2006 Dec. 25(10):1254-6. [Medline].

  54. Gee SN, Zakhary L, Keuthen N, Kroshinsky D, Kimball AB. A survey assessment of the recognition and treatment of psychocutaneous disorders in the outpatient dermatology setting: how prepared are we?. J Am Acad Dermatol. 2013 Jan. 68(1):47-52. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.